Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Intellia Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
16.5
26.1
30.4
43.1
58
33.1
52.1
36.3
57.9
67.7
Cost of revenue
0
0
0
0
Gross profit
30.4
43.1
58
33.1
Research and development
31.8
67.6
89.1
108
150
230
420
435
466
389
General and administrative
16.8
28
32.2
41.1
44.2
71.1
90.3
116
126
120
Operating income
-32.2
-69.6
-90.9
-106
-137
-268
-458
-515
-534
-441
Interest income
0.53
2.01
5.53
6.84
2.35
1.28
8.54
49.8
47.8
29.2
Other non-operating income
6.84
2.35
-0.04
-16
34.1
15.2
28.3
Pre-tax income
-31.6
-67.5
Income tax
0
0
Net income
-31.6
-67.5
-85.3
-474
-134
-268
-474
-481
-519
-413
EBITDA
-31.1
-66.6
-86.4
-101
-130
-261
-451
-506
-524
-431
EPS, basic
-1.42
-1.88
-1.98
-2.11
-2.40
-3.78
-6.16
-5.42
-5.25
-3.81
EPS, diluted
-1.42
-1.88
-1.98
-2.11
-2.40
-3.78
-6.16
-5.42
-5.25
-3.81
Shares, basic (weighted)
22.2
36
43.1
0.05
56
70.9
77
88.8
98.8
108
Shares, diluted (weighted)
22.2
36
43.1
0.05
56
70.9
77
88.8
98.8
108
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
273
341
58.9
57.2
160
123
524
227
189
155
Short-term investments
255
223
437
625
669
685
412
294
Receivables
6.45
10.5
7.55
4.62
2.13
2.03
3.77
36.5
8.52
9.47
Other current assets
1.79
3.68
3.37
5.14
17
18.6
20.4
49.7
29.8
68.4
Total current assets
281
355
325
289
617
769
1,217
998
640
528
Property, plant and equipment
10.6
15.3
17.1
18
15.9
21
27.9
32.8
27.4
17.7
Lease right-of-use assets
19.1
39.1
79.1
133
115
219
106
Long-term investments
4.75
0
337
69.3
99.9
260
155
Other non-current assets
7.04
6.13
5.28
2.92
4.75
Total assets
299
376
347
334
676
1,294
1,520
1,301
1,191
842
Accounts payable
4.65
2.17
2.71
3.94
10.5
9.65
5.15
7.45
14.6
20.3
Accrued liabilities
5.9
8
10.7
13.3
25.6
43.3
60.9
67
55.4
49.9
Deferred revenue
20.2
21.2
27.1
12.7
22.5
63.8
43.8
22.1
20.7
7.29
Total current liabilities
30.7
31.4
40.6
35.6
64.3
126
127
115
111
104
Lease liabilities
12.6
33.6
64.9
114
96.7
190
66.8
Other non-current liabilities
0.29
0.17
0.01
0
Total liabilities
89.1
75.6
69.4
64.4
149
254
285
251
319
171
Paid-in capital
263
422
479
570
962
1,746
2,420
2,711
3,049
3,260
Retained earnings
-53.6
-121
-201
-301
-435
-703
-1,177
-1,658
-2,177
-2,590
Other comprehensive income
-0.03
0.26
0
-2.63
-7.46
-2.26
0.61
1.03
Shareholders' equity
210
301
278
270
527
1,040
1,236
1,050
872
671
Total equity
210
301
278
270
527
1,040
1,236
1,050
872
671
Total liabilities and equity
299
376
347
334
676
1,294
1,520
1,301
1,191
842
Shares outstanding
36
42.4
45.2
50.2
66.2
74.5
87.1
93
102
116
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-31.6
-67.5
-85.3
-99.5
-134
-268
-474
-481
-519
-413
Depreciation and amortization
1.1
2.99
4.46
5.59
6.31
6.89
7.57
8.98
10.3
9.77
Stock-based compensation
6.72
15.3
17
15.1
19.9
47
91.4
134
154
80.2
Change in receivables
-5.45
-4.02
2.92
2.93
2.49
0.1
-1.74
-32.7
27.9
-0.95
Change in payables
1.78
-0.49
0.23
1.88
5.06
0.53
-4.58
2.52
6.8
5.99
Cash from operations
36.1
-65.3
-61.3
-103
-49.9
-225
-333
-394
-349
-395
Capital expenditures
-6.17
-10.1
-6.36
-6.79
-3.59
-12.8
-13.6
-14
-5.78
-1.13
Acquisitions
-0.29
-0.29
-0.29
Purchases of investments
-255
-297
-474
-1,021
-429
-904
-936
-323
Sales and maturities of investments
329
263
486
648
887
1,067
552
Cash from investing
-6.17
-10.1
-261
25.2
-214
-551
160
-31.3
126
228
Stock issued
171
141
28.5
72.3
11.6
1,818
14.5
120
177
128
Cash from financing
167
143
40.2
76.4
372
737
583
130
186
131
Net change in cash
197
67.6
-282
-1.63
107
-39.1
410
-295
-37.6
-35.2
Free cash flow
29.9
-75.4
-67.6
-110
-53.5
-238
-347
-408
-355
-396
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $11.75 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-711.7%
Operating income / revenue.
EBITDA margin
-696.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-672.2%
Net income / revenue.
FCF margin
-586.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-582.5%
Cash from operations / revenue.
Return on equity (ROE)
-55.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-46.7%
Net income / average total assets.
Return on invested capital (ROIC)
-53.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
582.7%
Research and development expense / revenue.
Stock-based pay / revenue
114.1%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
3.4%
Capital expenditures / revenue.
D&A / revenue
15.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
16.9%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
9.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
3.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-23.0%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-18.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
5.0%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-29.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-17.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
4.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
9.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
12.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
14.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.65x
Current assets / current liabilities.
Quick ratio
5.61x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
5.51x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.45
Revenue / diluted weighted shares.
FCF per share
-$2.61
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.60
Cash from operations / diluted weighted shares.
Book value per share
$5.20
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
27.7x
Market cap / revenue.
P/B
2.26x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.26x
Market cap / tangible book value, when positive.
EV/Sales
20.3x
Enterprise value / revenue.
FCF yield
-21.2%
Free cash flow / market cap.
Earnings yield
-24.3%
Net income / market cap (the inverse of P/E).
What was Intellia Therapeutics, Inc.'s revenue in fiscal 2025?
Intellia Therapeutics, Inc. reported revenue of $67.7M for fiscal 2025, 16.9% higher than the year before.
Was Intellia Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $412.7M.
How much free cash flow did Intellia Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $394.7M minus capital expenditures of $1.1M left free cash flow of -$395.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.